Tenaya Therapeutics Ownership

TNYA Stock  USD 3.57  0.28  8.51%   
Tenaya Therapeutics shows a total of 79.22 Million outstanding shares. The majority of Tenaya Therapeutics outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Tenaya Therapeutics to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Tenaya Therapeutics. Please pay attention to any change in the institutional holdings of Tenaya Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in stocks such as Tenaya Therapeutics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Tenaya Therapeutics, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
The current year's Dividend Paid And Capex Coverage Ratio is expected to grow to -78.26. As of November 30, 2024, Common Stock Shares Outstanding is expected to decline to about 53.3 M. The current year's Net Loss is expected to grow to about (105.7 M).
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tenaya Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
For information on how to trade Tenaya Stock refer to our How to Trade Tenaya Stock guide.

Tenaya Stock Ownership Analysis

About 74.0% of the company shares are owned by institutional investors. The book value of Tenaya Therapeutics was at this time reported as 1.42. The company recorded a loss per share of 1.44. Tenaya Therapeutics had not issued any dividends in recent years. Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. The company was incorporated in 2016 and is headquartered in South San Francisco, California. Tenaya Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 135 people. To find out more about Tenaya Therapeutics contact Faraz MBA at 650 825 6990 or learn more at https://www.tenayatherapeutics.com.
Besides selling stocks to institutional investors, Tenaya Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Tenaya Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Tenaya Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.

Tenaya Therapeutics Quarterly Liabilities And Stockholders Equity

140.58 Million

Tenaya Therapeutics Insider Trades History

Only 1.17% of Tenaya Therapeutics are currently held by insiders. Unlike Tenaya Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Tenaya Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Tenaya Therapeutics' insider trades
 
Covid

Tenaya Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Tenaya Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Tenaya Therapeutics backward and forwards among themselves. Tenaya Therapeutics' institutional investor refers to the entity that pools money to purchase Tenaya Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Fmr Inc2024-09-30
1.3 M
Geode Capital Management, Llc2024-09-30
1.3 M
State Street Corp2024-06-30
M
Euclidean Capital Llc2024-09-30
M
Adage Capital Partners Gp Llc2024-06-30
1000 K
Schonfeld Strategic Advisors Llc2024-09-30
917.4 K
Alphabet Inc2024-09-30
915.7 K
Abrdn Plc2024-09-30
550.7 K
Stepstone Group Llc2024-06-30
462.2 K
Column Group Llc2024-09-30
9.4 M
Ra Capital Management, Llc2024-09-30
M
Note, although Tenaya Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Tenaya Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tenaya Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tenaya Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tenaya Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Chihiro Saito over a week ago
Disposition of 2258 shares by Chihiro Saito of Tenaya Therapeutics at 2.12 subject to Rule 16b-3
 
Burroughs Amy L. over a month ago
Acquisition by Burroughs Amy L. of 34000 shares of Tenaya Therapeutics at 2.04 subject to Rule 16b-3
 
Column Group Iii Gp, Lp over two months ago
Acquisition by Column Group Iii Gp, Lp of 2222222 shares of Tenaya Therapeutics at 4.5 subject to Rule 16b-3
 
Saito Chihiro over three months ago
Disposition of 49000 shares by Saito Chihiro of Tenaya Therapeutics at 20.65 subject to Rule 16b-3
 
Chihiro Saito over three months ago
Acquisition by Chihiro Saito of 25000 shares of Tenaya Therapeutics subject to Rule 16b-3
 
Chihiro Saito over three months ago
Disposition of tradable shares by Chihiro Saito of Tenaya Therapeutics subject to Rule 16b-3
 
Column Group Iii Gp, Lp over six months ago
Acquisition by Column Group Iii Gp, Lp of 2222222 shares of Tenaya Therapeutics at 4.5 subject to Rule 16b-3
 
Timothy Hoey over six months ago
Disposition of 4007 shares by Timothy Hoey of Tenaya Therapeutics at 3.81 subject to Rule 16b-3
 
Timothy Hoey over six months ago
Disposition of 4681 shares by Timothy Hoey of Tenaya Therapeutics at 5.86 subject to Rule 16b-3
 
Timothy Hoey over six months ago
Tenaya Therapeutics exotic insider transaction detected
 
Ali Faraz over six months ago
Acquisition by Ali Faraz of 85000 shares of Tenaya Therapeutics subject to Rule 16b-3
 
Timothy Hoey over six months ago
Sale by Timothy Hoey of 6369 shares of Tenaya Therapeutics

Tenaya Therapeutics Outstanding Bonds

Tenaya Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Tenaya Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Tenaya bonds can be classified according to their maturity, which is the date when Tenaya Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Tenaya Therapeutics Corporate Filings

F4
18th of November 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
13A
14th of November 2024
An amended filing to the original Schedule 13G
ViewVerify
8K
6th of November 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
17th of September 2024
Other Reports
ViewVerify

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Tenaya Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Tenaya Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Tenaya Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Tenaya Therapeutics Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tenaya Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.
For information on how to trade Tenaya Stock refer to our How to Trade Tenaya Stock guide.
You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tenaya Therapeutics. If investors know Tenaya will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tenaya Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.44)
Return On Assets
(0.46)
Return On Equity
(0.84)
The market value of Tenaya Therapeutics is measured differently than its book value, which is the value of Tenaya that is recorded on the company's balance sheet. Investors also form their own opinion of Tenaya Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Tenaya Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tenaya Therapeutics' market value can be influenced by many factors that don't directly affect Tenaya Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tenaya Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tenaya Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tenaya Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.